IDXX:NSD-IDEXX Laboratories Inc (USD)

COMMON STOCK | Diagnostics & Research |

Last Closing

USD 415.3

Change

0.00 (0.00)%

Market Cap

USD 35.55B

Volume

0.65M

Analyst Target

USD 427.40
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It offers in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology, and coagulation analyzers; and SNAP rapid assays test kits. The company also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, it offers diagnostic tests, services, and related instrumentation for manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-16 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
NTRA Natera Inc

N/A

USD 21.03B
ICLR ICON PLC

N/A

USD 16.66B
ILMN Illumina Inc

N/A

USD 14.06B
MEDP Medpace Holdings Inc

N/A

USD 9.97B
EXAS EXACT Sciences Corporation

N/A

USD 9.13B
GH Guardant Health Inc

N/A

USD 4.85B
RDNT RadNet Inc

N/A

USD 4.54B
SHC Sotera Health Co

N/A

USD 3.23B
VCYT Veracyte Inc

N/A

USD 3.18B
WGS GeneDx Holdings Corp.

N/A

USD 2.75B

ETFs Containing IDXX

PETZ:LSE 8.59 % 0.00 %

N/A

N/A
KATZ:XETRA 8.16 % 0.00 %

N/A

N/A
PETZ:SW 8.16 % 0.00 %

N/A

N/A
ZIG The Acquirers Fund ETF 3.71 % 0.00 %

N/A

USD 0.04B
UMDV:SW iShares US Medical Device.. 3.57 % 0.00 %

N/A

N/A
IHI iShares U.S. Medical Devi.. 0.00 % 0.43 %

N/A

N/A
JMIN 0.00 % 0.12 %

N/A

N/A
YXM.A:CA 0.00 % 1.49 %

N/A

N/A
YXM.D:CA 0.00 % 1.53 %

N/A

N/A
JUMF:XETRA 0.00 % 0.00 %

N/A

N/A
LCG Sterling Capital Focus Eq.. 0.00 % 0.00 %

N/A

USD 0.03B
JUMF:F 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.45% 71% C- 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.45% 71% C- 65% D
Trailing 12 Months  
Capital Gain -21.61% 51% F 35% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -21.61% 51% F 35% F
Trailing 5 Years  
Capital Gain 92.38% 83% B 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 92.38% 83% B 66% D+
Average Annual (5 Year Horizon)  
Capital Gain 10.15% 60% D- 62% D
Dividend Return 10.15% 60% D- 59% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 43.43% 71% C- 44% F
Risk Adjusted Return 23.37% 81% B- 56% F
Market Capitalization 35.55B 100% F 97% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.